[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coccidioidomycosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coccidioidomycosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100223746","pathogenesis-and-genetics-of-disseminated-or-refractory-coccidioidomycosis-100223746",false,"NCT02190266","Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis","The Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis","* INCLUSION CRITERIA:\n\nTo be eligible for this study, potential participants must meet the following criteria:\n\n1. Age \\>= 2 years old.\n\n   a. Enrollment of pediatric patients who are acutely ill or likely to become acutely ill will be deferred until a time when they are considered medically stable by the PI.\n2. Have a positive Coccidioides antigen load or culture proven (a) refractory pulmonary coccidioidomycosis or (b) disseminated coccidioidomycosis.\n\n   1. Refractory pulmonary coccidioidomycosis must have occurred for at least 6 months and includes progressive pulmonary involvement without significant pulmonary cavitation.\n   2. Disseminated CM is coccidioidomycosis infection in one or more regions outside of the chest.\n3. Agree to undergo genetic testing.\n4. Allow their samples to be stored for future research.\n\nEXCLUSION CRITERIA:\n\n1. HIV infection\n2. Currently taking more than 20 mg\u002Fday of prednisone or undergoing active immunosuppressive therapy in the opinion of the investigator\n3. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent.","ALL","2 Years","100 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Coccidioidomycosis is caused by a fungus that grows in the southwest United States and parts of Mexico and South America. This disease is caused by breathing dust containing the fungus. It can lead to serious lung and breathing problems. Rarely, the fungus can infect other body parts. This is called disseminated coccidioidomycosis (DCM). If the fungus stays in the lungs for more than 6 months, it is called refractory coccidioidomycosis (RCM). People with DCM or RCM may have difficulty fighting off infection because of immune system problems. Researchers want to study the immune systems of people with DCM or RCM, to learn more about the disease and the best ways to treat it. They also want to learn more about the types of people that get DCM or RCM and about the fungus that causes it.\n\nObjectives:\n\n\\- To learn more about DCM and RCM, the fungus that causes these diseases, and the people who get them.\n\nEligibility:\n\n\\- People over age 2 with DCM or RCM.\n\nDesign:\n\n* Participants will be screened with a review of their medical records.\n* At the initial visit, participants will have:\n* Medical history and physical exam\n* Blood and urine tests. Some blood may be used for genetic testing. The samples will not include participants names. Participants will be notified only if the tests show something urgent about their DCM\u002FRCM. Researchers think this sort of problem will be rare.\n* Questionnaire about their DCM\u002FRCM\n* Sputum (mucus) collection. They will spit into a cup.\n* Participants will have 1 follow-up visit per year. They will have blood tests. They may have other procedures to treat their DCM\u002FRCM.",[25],"Coccidioidomycosis",[27,28,29,30,31,32],"Extrapulmonary","Immunodeficiency","Genetics","Infection","Fungal","Natural History","RECRUITING","2026-10-10",{"date":36,"type":37},"2026-10-13","ACTUAL",{"date":39,"type":37},"2014-09-02",{"date":41,"type":21},"2029-07-31",{"name":43,"class":44},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100647593","phase-2-a-phase-ii-randomized-study-to-evaluate-measures-for-endpoint-derivation-in-patients-with-progressive-or-refractory-disseminated-coccidioidomycosis-dcm--treated-with-olorofim-plus-baseline-soc-or-placebo-plus-baseline-soc-100647593","NCT07712484","A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care","COCCIMETRICS: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM) Treated With Olorofim Plus Baseline Standard of Care (SOC) or With Placebo Plus Baseline SOC","COCCIMETRICS","Inclusion Criteria:\n\n* Male and female patients, English- or Spanish-speaking, aged ≥18 years and weighing ≥40 kg.\n* Patients with progressive or refractory disseminated coccidioidomycosis (DCM) involving extra-pulmonary sites with or without ongoing active disease in lungs.\n* Standard of Care therapy for DCM to date has included 2 different triazoles (with or without a course of intravenous amphotericin B).\n\nExclusion Criteria:\n\n* Patients who are unconscious.\n* Women who are pregnant or breastfeeding.\n* Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug.\n* Patients with or planned placement of indwelling CNS devices.\n* Patients receiving intrathecal amphotericin B at the time of study enrolment.\n* Coccidioidomycosis limited to fibro-cavitary pulmonary disease.\n* All bothersome DCM-related symptoms at study entry are due to irreversible damage (e.g., neurologic deficits due to stroke).\n* Other than cutaneous fungal infections treated topically and Pneumocystis jirovecii infections, patients with a second fungal infection requiring systemic antifungal treatment or prophylaxis.\n* Patients with microbiological findings or other potential conditions that are temporally related and suggest a different than study indication etiology for the clinical features.\n* Patients living with Human immunodeficiency virus (HIV) unless for at least 6 months prior to enrollment:\n\n  1. Are receiving antiretroviral therapy AND\n  2. Have no evidence of current clinical progression resulting from HIV infection.\n* Patients who have received prior treatment with olorofim\u002FF901318.\n* Patients receiving treatment limited to supportive care due to predicted short survival time.\n* Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥500 msec, or at high risk for QT\u002FQTc prolongation.\n* Evidence of hepatic dysfunction.","18 Years",{"count":56,"type":21},50,"INTERVENTIONAL",[59],"PHASE2","The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).",[25,62,63,64,65,66,67,68],"Disseminated Fungal Infection","Coccidioides Infection","Coccidioides Immitis Infection","Coccidioides Posadasii Infection","Coccidioidomycosis Infection","San Joaquin Valley Fever","Valley Fever",[70,25,71,72,68,73,74,75,76,77,78,79,80],"Cocci","Disseminated coccidioidomycosis","Olorofim","Patient-reported outcomes","Valley Fever Patient Reported Outcome","Symptom assessment","Endpoint development","Outcome measure validation","Quality of life","Fungal infection","Invasive fungal disease","NOT_YET_RECRUITING","2026-09-17",{"date":84,"type":37},"2026-09-22",{"date":86,"type":21},"2026-12",{"date":88,"type":21},"2028-07",{"name":90,"class":91},"F2G Ltd","INDUSTRY",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":57,"phases":100,"briefSummary":101,"conditions":102,"keywords":107,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":122},"100654891","phase-2-platform-trial-for-salvage-consolidation-therapy-in-dimorphic-fungi-100654891","NCT07804368","Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi","Inclusion Criteria:\n\n* Diagnosis of coccidioidomycosis, blastomycosis, or histoplasmosis and on active therapy\n* Age 18 years or older\n* Anticipated need for at least 6 additional months of antifungal therapy at enrollment\n* Intolerance, failure, or unavailability of current first-line consolidation therapy\n\nExclusion Criteria:\n\n* Currently hospitalized\n* Central nervous system involvement of coccidioidomycosis, blastomycosis, or histoplasmosis\n* Previous administration of or allergy to study drug\n* Any condition for which participation would not be in the best interest of the participant or that could limit protocol-specified assessments\n* Females of childbearing potential\n* Breast Cancer Resistance Protein substrate medication interaction that cannot be managed by switching medication, discontinuation, 50% dose reduction, or use of the lowest dose\n* Children\n* Pregnant women\u002Fpersons\n* Fetuses\n* Neonates\n* Prisoners\n* Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent",{"count":99,"type":21},30,[59],"This Phase II platform trial will evaluate the safety, tolerability, and effectiveness of investigational antifungal agents as salvage or consolidation therapy in adults with dimorphic fungal infections, including coccidioidomycosis, blastomycosis, and histoplasmosis.\n\nThe study will enroll adults who are receiving active antifungal therapy and who have intolerance, failure, or unavailability of standard first-line consolidation therapy. The first investigational agent evaluated in the platform trial is oteseconazole.\n\nParticipants will receive study drug and complete follow-up assessments for symptom status, functional status, adverse events, laboratory safety, study drug discontinuation, and quality of life. Participants will be followed during therapy and for up to 6 months after therapy.",[25,103,104,105,106],"Blastomycosis","Histoplasmosis","Dimorphic Fungal Infection","Endemic Mycoses",[108,109,110,25,111],"Dimorphic fungi","Endemic mycoses","Salvage therapy","Antifungal therapy","2026-08-31",{"date":114,"type":37},"2026-09-04",{"date":116,"type":21},"2026-12-01",{"date":118,"type":21},"2028-12-01",{"name":120,"class":121},"University of Minnesota","OTHER",4]